Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BCG vaccine - Serum Institute of India/Vakzine Projekt Management

Next Previous
Drug Profile

BCG vaccine - Serum Institute of India/Vakzine Projekt Management

Alternative Names: BCG VPM 1002; BCG-vaccine-Vakzine-Projekt-Management; rBCG-delta-ureC-Hly; rBCGdeltaUreCHly; VPM-1002; VPM-1002BC

Latest Information Update: 08 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Max Planck Institute for Infection Biology
  • Developer Max Planck Institute for Infection Biology; Serum Institute of India; Swiss Group for Clinical Cancer Research; Vakzine Projekt Management
  • Class COVID-19 vaccines; Tuberculosis vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III COVID 2019 infections; Respiratory tract infections; Tuberculosis
  • Phase I/II Bladder cancer

Most Recent Events

  • 12 Oct 2021 Vakzine Projekt Management completes phase III trial in Respiratory tract infections (Prevention) in Germany (Transdermal) (EudraCT2020-001675-33) (NCT04435379)
  • 09 Sep 2021 Serum Institute of India completes the phase III COBRA trial in COVID-2019 infections (Prevention) in Canada and India(Intradermal) (NCT04439045)
  • 19 Nov 2020 Swiss Group for Clinical Cancer Research plans a phase II trial for Bladder cancer in Switzerland (Intravesicular) in February 2021 (NCT04630730)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top